Abstract
Description
The ‘Oncology Partnering Terms and Agreements’ report provides comprehensive
understanding and unprecedented access to the oncology partnering deals and
agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why
companies enter oncology partnering deals. The majority of deals are discovery
or development stage whereby the licensee obtains a right or an option right
to license the licensors oncology technology. These deals tend to be
multicomponent, starting with collaborative R&D, and commercialization of
outcomes.
Understanding the flexibility of a prospective partner's negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases do not.
This report contains over 2,700 links to online copies of actual oncology
deals and contract documents as submitted to the Securities Exchange
Commission by companies and their partners. Contract documents provide the
answers to numerous questions about a prospective partner's flexibility on a
wide range of important issues, many of which will have a significant impact
on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of oncology
dealmaking and business activities. Chapter 1 provides an introduction to the
report, whilst chapter 2 provides an overview of the trends in oncology
dealmaking since 2007, including details of average headline, upfront,
milestone and royalty terms.
Chapter 3 provides a review of the leading oncology deals since 2007. Deals
are listed by headline value, signed by bigpharma, most active bigpharma, and
most active of all biopharma companies. Where the deal has an agreement
contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of oncology deals, as
well as contract documents available in the public domain. Where available,
each deal title links via Weblink to an online version of the actual contract
document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of oncology partnering
deals signed and announced since 2007, where a contract document is available
in the public domain. The chapter is organized by stage of development at
signing, deal type (collaborative R&D, co-promotion, licensing etc),
technology type and specific therapy focus. Each deal title links via Weblink
to an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in oncology partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
oncology technologies and products.
Key benefits
‘Oncology Partnering Terms and Agreements’ provides the reader with the following key benefits:
- In-depth understanding of oncology deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 2,700 actual oncology contracts entered into
by the world's biopharma companies
- Detailed access to actual oncology contracts enter into by the leading
fifty bigpharma companies
- Insight into the terms included in a oncology agreement, together with
real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
Report scope
‘Oncology Partnering Terms and Agreements’ is intended to provide the reader
with an in-depth understanding and access to oncology trends and structure of
deals entered into by leading companies worldwide.
‘Oncology Partnering Terms and Agreements’ includes:
- Trends in oncology dealmaking in the biopharma industry since 2007
- Analysis of oncology deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life oncology deals
- Access to over 2,700 oncology contract documents
- The leading oncology deals by value since 2007
- Most active oncology dealmakers since 2007
- The leading oncology partnering resources
In ‘Oncology Partnering Terms and Agreements’, the available contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
The ‘Oncology Partnering Terms and Agreements’ report provides comprehensive
access to available deals and contract documents for over 2,700 oncology deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise oncology rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal
type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in oncology dealmaking
- 2.1. Introduction
- 2.2. Oncology partnering over the years
- 2.3. Bigpharma oncology dealmaking activity
- 2.4. Bigpharma not active in oncology
- 2.5. Oncology partnering by deal type
- 2.6. Oncology partnering by industry sector
- 2.7. Oncology partnering by stage of development
- 2.8. Oncology partnering by technology type
- 2.9. Oncology partnering by oncology indication
- 2.10. Average deal terms for oncology
- 2.10.1. Oncology headline values
- 2.10.2. Oncology upfront payments
- 2.10.3. Oncology milestone payments
- 2.10.4. Oncology royalty rates
Chapter 3 - Leading oncology deals
- 3.1. Introduction
- 3.2. Top oncology deals by value
- 3.3. Top oncology deals involving bigpharma
Chapter 4 - Bigpharma oncology deals
- 4.1. Introduction
- 4.2. How to use bigpharma partnering deals
- 4.3. Bigpharma oncology partnering company profiles
- Abbott
- Actavis
- Actelion
- Allergan
- Amgen
- Aspen Pharmacare
- Astellas
- AstraZeneca
- Baxter International
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- CSL
- Daiichi Sankyo
- Dainippon Sumitomo
- Eisai
- Eli Lilly
- Endo Pharmaceuticals
- Galderma
- Gilead Sciences
- GlaxoSmithKline
- Grifols
- Hospira
- Johnson & Johnson
- Kyowa Hakko Kirin
- Lundbeck
- Menarini
- Merck & Co
- Merck KGaA
- Mitsubishi Tanabe
- Novartis
- Novo Nordisk
- Otsuka
- Pfizer
- Purdue
- Roche
- Sanofi
- Servier
- Takeda
- Teva
- Valeant
- Watson
Chapter 5 - Oncology partnering contracts directory
- 5.1. Introduction
- 5.2. By deal type
- Asset purchase
- Assignment
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Litigation
- Loan
- Manufacturing
- Marketing
- Material transfer
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub-license
- Supply
- Technology transfer
- Termination
- Warranty
- 5.3. By stage of development
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
- Regulatory
- Marketed
- Formulation
- 5.4. By technology type
- Analysis
- Animal models
- Antibodies
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- Drug delivery
- Enabling technology
- Enviromental
- Epigenetics
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Implant
- Industrial chemicals
- In vitro models
- Nanotechnology
- Natural product
- Oligonucleotide
- Orphan drug
- Peptides
- Personalised medicine
- Pharmacogenomics
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Software tools
- Stem cells
- Vaccines
Chapter 6 - Oncology dealmaking by indication
- 6.1. Introduction
- 6.2. Deals by therapeutic indication
- Oncology
- Adenocarcinoma
- Basal cell carcinoma
- Bile duct cancer
- Bladder cancer
- Bone cancer
- Brain cancer
- Breast cancer
- Cervical cancer
- Colorectal cancer
- Endometrial
- Esophageal cancer
- Gastric cancer
- Head and neck cancer
- Kaposi's sarcoma
- Kidney cancer
- Leukemia
- Acute lymphoblastic leukemia
- Acute myelogenous leukemia
- Chronic lymphocytic leukemia
- Chronic myelogenous leukemia
- Liver cancer
- Lung cancer
- Non small cell lung cancer
- Small cell lung cancer
- Lymphoma
- Hodgkin's lymphoma
- Non Hodgkin's lymphoma
- Melanoma
- Mesothelioma
- Metastases
- Bone metastases
- Multiple myeloma
- Neuroblastoma
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Renal cell carcinoma
- Sarcoma
- Non-melanoma skin cancer
- Solid tumors
- Symptoms
- Alopecia
- Cachexia
- Cancer pain
- Neuropathic
- Chemotherapy
- Dysphagia
- Lymphoedema
- Nausea
- Oral mucositis
- Radiotherapy
- Vomiting
- Testicular cancer
- Thyroid cancer
Chapter 7 - Partnering resource center
- 7.1. Online partnering
- 7.2. Partnering events
- 7.3. Further reading on dealmaking
About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form - Reports
- Order Form - Therapy Reports
Appendices
- Appendix 1 - Directory of oncology deals by company A-Z 2007-2012
- Appendix 2 - Directory of oncology deals by deal type 2007-2012
- Appendix 3 - Directory of oncology deals by stage of development 2007-2012
- Appendix 4 - Directory of oncology deals by technology type 2007-2012
- Appendix 5 - Deal type definitions
Table of figures
- Figure 1: Oncology partnering since 2007
- Figure 2: Bigpharma - top 50 - Oncology deals 2007 to 2012
- Figure 3: Bigpharma oncology deal frequency - 2007 to 2012
- Figure 4: Inactive bigpharma in oncology 2007-2012
- Figure 5: Oncology partnering by deal type since 2007
- Figure 6: Oncology partnering by industry sector since 2007
- Figure 7: Oncology partnering by stage of development since 2007
- Figure 8: Oncology partnering by technology type since 2007
- Figure 9: Oncology partnering by oncology target since 2007
- Figure 10: Oncology deals with a headline value
- Figure 11: Oncology deal headline value distribution, US$million -
discovery stage
- Figure 12: Oncology deal headline value distribution, US$million -
preclinical stage
- Figure 13: Oncology deal headline value distribution, US$million - phase I
stage
- Figure 14: Oncology deal headline value distribution, US$million - phase
II stage
- Figure 15: Oncology deal headline value distribution, US$million - phase
III stage
- Figure 16: Oncology deal headline value distribution, US$million -
regulatory stage
- Figure 17: Oncology deal headline value distribution, US$million -
marketed stage
- Figure 18: Summary median headline value by stage of development, 2007-2012
- Figure 19 Oncology deals with upfront payment values
- Figure 20: Oncology deal upfront payment distribution, US$million -
discovery stage
- Figure 21: Oncology deal upfront payment distribution, US$million -
preclinical stage
- Figure 22: Oncology deal upfront payment distribution, US$million - phase
I stage
- Figure 23: Oncology deal upfront payment distribution, US$million - phase
II stage
- Figure 24: Oncology deal upfront payment distribution, US$million - phase
III stage
- Figure 25: Oncology deal upfront payment distribution, US$million -
regulatory stage
- Figure 26: Oncology deal upfront payment distribution, US$million -
marketed stage
- Figure 27: Summary median upfront payments by stage of development,
2007-2012
- Figure 28: Oncology deals with milestone payments
- Figure 29: Oncology deal milestone distribution, US$million - discovery
stage
- Figure 30: Oncology deal milestone distribution, US$million - preclinical
stage
- Figure 31: Oncology deal milestone distribution, US$million - phase I stage
- Figure 32: Oncology deal milestone distribution, US$million - phase II
stage
- Figure 33: Oncology deal milestone distribution, US$million - phase III
stage
- Figure 34: Oncology deal milestone distribution, US$million - regulatory
stage
- Figure 35: Oncology deal milestone distribution, US$million - marketed
stage
- Figure 36: Oncology deals with royalty rates, %
- Figure 37: Oncology deal royalty rate distribution, US$million - discovery
stage
- Figure 38: Oncology deal royalty rate distribution, US$million -
preclinical stage
- Figure 39: Oncology deal royalty rate distribution, US$million - phase I
stage
- Figure 40: Oncology deal royalty rate distribution, US$million - phase II
stage
- Figure 41: Oncology deal royalty rate distribution, US$million - phase III
stage
- Figure 42: Oncology deal royalty rate distribution, US$million -
regulatory stage
- Figure 44: Summary median royalty rate by stage of development, 2007-2012
- Figure 45: Top oncology deals by value since 2007
- Figure 46: Top oncology deals signed by bigpharma value since 2007
- Figure 47: Online partnering resources
- Figure 48: Forthcoming partnering events
Oncology Partnering Terms and Agreements published by Current Partnering, a division of Wildwood Ventures Limited. This report consists of 1117 Pages and the price starts from US $ 2995.
The contents of this page may be different from the latest version. Please contact us for details.
